Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from ImmunityBio ( (IBRX) ) is now available.
On January 23, 2026, ImmunityBio, Inc. amended a $505 million Second Amended and Restated Convertible Promissory Note originally dated December 10, 2024, with Nant Capital, LLC, an affiliate of Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong. The change gives the noteholder the right to convert any portion of the outstanding principal into ImmunityBio common stock at any time before maturity, whereas partial conversion had not been permitted previously, potentially providing the company with added flexibility in managing its capital structure and aligning a major insider-creditor more closely with equity holders; no other terms of the note were modified.
The most recent analyst rating on (IBRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.
Spark’s Take on IBRX Stock
According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.
The score is held back primarily by weak financial health (negative profitability, negative equity, and negative operating/free cash flow). This is partially offset by strong technical momentum (price above major moving averages with positive MACD) and supportive recent regulatory approvals/expansion events, while valuation remains constrained by losses (negative P/E) and no dividend yield data.
To see Spark’s full report on IBRX stock, click here.
More about ImmunityBio
ImmunityBio, Inc. operates in the biopharmaceutical industry, developing immunotherapy-based treatments that leverage the body’s immune system to fight cancer and infectious diseases. The company focuses on innovative therapeutic platforms aimed at improving clinical outcomes in oncology and related indications.
Average Trading Volume: 23,143,086
Technical Sentiment Signal: Strong Buy
Current Market Cap: $6.35B
Learn more about IBRX stock on TipRanks’ Stock Analysis page.